Pomerantz LLP has filed a class action lawsuit against Intellia Therapeutics (NTLA) following the company's announcement of strategic changes, including workforce reduction and drug development shifts. On January 9, 2025, Intellia disclosed plans to focus on NTLA-2002 and nex-z while discontinuing NTLA-3001, resulting in a 27% workforce cut and approximately $8 million in restructuring charges. The stock price dropped 15.14% on January 10, 2025, prompting the legal action.